Compare FDS & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDS | GKOS |
|---|---|---|
| Founded | 1978 | 1998 |
| Country | United States | United States |
| Employees | 6258 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.0B |
| IPO Year | 1996 | 2015 |
| Metric | FDS | GKOS |
|---|---|---|
| Price | $264.01 | $167.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $284.80 | $126.92 |
| AVG Volume (30 Days) | 814.3K | ★ 822.1K |
| Earning Date | 03-31-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 11.79 | N/A |
| EPS | ★ 11.16 | N/A |
| Revenue | ★ $1,435,351,000.00 | $507,442,000.00 |
| Revenue This Year | $7.16 | $23.32 |
| Revenue Next Year | $5.55 | $27.43 |
| P/E Ratio | $23.70 | ★ N/A |
| Revenue Growth | 6.31 | ★ 32.33 |
| 52 Week Low | $185.00 | $73.16 |
| 52 Week High | $398.50 | $184.00 |
| Indicator | FDS | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 72.12 |
| Support Level | $245.31 | $94.16 |
| Resistance Level | $274.72 | N/A |
| Average True Range (ATR) | 11.11 | 7.62 |
| MACD | 1.01 | 0.52 |
| Stochastic Oscillator | 40.20 | 56.01 |
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.